Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

Last updated: November 3, 2005
Sponsor: National Institute on Drug Abuse (NIDA)
Overall Status: Completed

Phase

3

Condition

Opioid Use Disorder

Treatment

N/A

Clinical Study ID

NCT00000302
NIDA-09260-5
P50-09260-5
  • Ages 21-50
  • All Genders

Study Summary

The purpose of this study is to compare liquid and tablet buprenorphine formulations.

Eligibility Criteria

Inclusion

Inclusion Criteria: M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Currently enrolled in theoutpatient protocol comparing liquid and tablet formulations of Buprenorphine. Agreeable toconditions of study and signed informed consent.

Exclusion

Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/ornursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acutehepatitis. Other medical conditions that deem participation to be unsafe.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Participants were inducted on either liquid or tablet buprenorphine, in a double-blind, double-dummy manner. They each reached a steady state by the second week, and were scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.

Connect with a study center

  • Friends Research Institute

    Los Angeles, California 90025
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.